NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years |
|
|
| Active, not recruiting | 2/3 | 3600 | Europe, US, RoW | Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), Placebo, Sodium chloride 0.9% (BP, sterile) | Novavax | COVID-19 | 11/23 | 09/25 | | |
NCT05084508 / 2022-001910-21: A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age |
|
|
| Active, not recruiting | 2 | 800 | Europe, US, RoW | Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Marketed varicella vaccine Lot 1, Marketed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine | GlaxoSmithKline, GlaxoSmithKline Biologicals SA (GSK) | Chickenpox | 02/24 | 07/24 | | |
